TY  - JOUR
AU  - Rodríguez-Moreno, Juan Francisco
AU  - Apellaniz-Ruiz, María
AU  - Roldan-Romero, Juan María
AU  - Durán, Ignacio
AU  - Beltrán, Luis
AU  - Montero-Conde, Cristina
AU  - Cascón, Alberto
AU  - Robledo, Mercedes
AU  - García-Donas, Jesus
AU  - Rodríguez-Antona, Cristina
PY  - 2017
DO  - 10.6004/jnccn.2017.7018
UR  - http://hdl.handle.net/10668/11782
T2  - Journal of the National Comprehensive Cancer Network : JNCCN
AB  - mTOR pathway inhibitors are important drugs for the treatment of advanced renal cell carcinoma (RCC). However, no valid predictive markers have been identified to guide treatment selection and identify patients who are sensitive to these drugs....
LA  - en
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - Bone Neoplasms
KW  - Carcinoma, Renal Cell
KW  - Denosumab
KW  - Female
KW  - Gain of Function Mutation
KW  - Humans
KW  - Kidney Neoplasms
KW  - Liver Neoplasms
KW  - Magnetic Resonance Imaging
KW  - Mechanistic Target of Rapamycin Complex 1
KW  - Metastasectomy
KW  - Middle Aged
KW  - Mutation, Missense
KW  - Positron Emission Tomography Computed Tomography
KW  - Protein Kinase Inhibitors
KW  - Response Evaluation Criteria in Solid Tumors
KW  - Signal Transduction
KW  - Sirolimus
KW  - TOR Serine-Threonine Kinases
KW  - Treatment Outcome
KW  - Tumor Suppressor Proteins
KW  - Ubiquitin Thiolesterase
KW  - Exome Sequencing
TI  - Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR-Activating Mutation.
TY  - research article
VL  - 15
ER  -